{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:26:44Z","timestamp":1793845604539,"version":"4.6.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.smim.2026.102029","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:51:11Z","timestamp":1777996271000},"page":"102029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Access to CAR-T therapy in Latin America: Barriers, gaps, and pathways forward"],"prefix":"10.1016","volume":"82","author":[{"given":"Jorge","family":"Contreras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Herschbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimisha","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-8246","authenticated-orcid":false,"given":"Monica L.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2026.102029_bib1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2026.102029_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/OP.22.00819","article-title":"Chimeric antigen receptor T-cell therapy for hematologic malignancies: a practical review","volume":"19","author":"Strati","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.smim.2026.102029_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.smim.2026.102029_bib4","first-page":"41","article-title":"Relationship between the nurses' reward fit and job involvement. Organizational commitment","volume":"36","author":"Kim","year":"1997","journal-title":"Taehan Kanho"},{"key":"10.1016\/j.smim.2026.102029_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn1902","article-title":"The translational gap for gene therapies in low- and middle-income countries","volume":"16","author":"Doxzen","year":"2024","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.smim.2026.102029_bib6","article-title":"Drug development in LMICs: could the emerging Indian model usher the southeast Asian region?","volume":"29","author":"Pant","year":"2024","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"10.1016\/j.smim.2026.102029_bib7","article-title":"Latin America and evolving oncotherapeutics using CAR T cells, conjugated antibodies, and bispecific antibodies","volume":"1","author":"Sackstein","year":"2025","journal-title":"Blood Glob. Hematol."},{"issue":"1","key":"10.1016\/j.smim.2026.102029_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-024-00747-6","article-title":"Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies","volume":"20","author":"Islam","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.smim.2026.102029_bib9","first-page":"714","article-title":"Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed\/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.smim.2026.102029_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.smim.2026.102029_bib11","article-title":"Clinical trials to gene therapy development and production in Brazil: a review","volume":"43","author":"Morales Saute","year":"2025","journal-title":"Lancet Reg. Health - Am."},{"key":"10.1016\/j.smim.2026.102029_bib12","article-title":"Advances and challenges for gene therapies in Brazil","volume":"43","author":"Campos de Carvalho","year":"2025","journal-title":"Lancet Reg. Health Am."},{"key":"10.1016\/j.smim.2026.102029_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jcyt.2024.03.492","article-title":"Challenges and opportunities for access to advanced therapy medicinal products in Brazil","volume":"26","author":"Sachetti","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.smim.2026.102029_bib14","article-title":"Advances and challenges for gene therapies in Brazil","volume":"43","author":"Campos de Carvalho","year":"2025","journal-title":"Lancet Reg. Health - Am."},{"key":"10.1016\/j.smim.2026.102029_bib15","first-page":"558","article-title":"Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.smim.2026.102029_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.46989\/001c.115793","article-title":"Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations","volume":"6","author":"Gatwood","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.smim.2026.102029_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/136087","article-title":"Human leukocyte antigen profiles of latin american populations: differential admixture and its potential impact on hematopoietic stem cell transplantation","volume":"2012","author":"Arrieta-Bolanos","year":"2012","journal-title":"Bone Marrow Res"},{"key":"10.1016\/j.smim.2026.102029_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1186\/s12864-018-5195-7","article-title":"Genetic ancestry, admixture and health determinants in Latin America","volume":"19","author":"Norris","year":"2018","journal-title":"BMC Genom."},{"key":"10.1016\/j.smim.2026.102029_bib19","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.smim.2026.102029_bib20","first-page":"216","article-title":"Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials","volume":"34","author":"Williams","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.smim.2026.102029_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States","volume":"124","author":"Zavala","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.smim.2026.102029_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/2159-8290.CD-24-0827","article-title":"Ancestral differences in anticancer treatment efficacy and their underlying genomic and molecular alterations","volume":"15","author":"Luo","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.smim.2026.102029_bib23","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1038\/s41588-024-01929-x","article-title":"Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia","volume":"56","author":"Stiff","year":"2024","journal-title":"Nat. Genet"},{"key":"10.1016\/j.smim.2026.102029_bib24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41586-023-06595-3","article-title":"Genotyping, sequencing and analysis of 140,000 adults from Mexico City","volume":"622","author":"Ziyatdinov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.smim.2026.102029_bib25","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1182\/blood-2022-170326","article-title":"Molecular landscape in acute myeloid leukemia (AML) patients (pts) from Mexico as an initial study to identify healthcare disparities in hispanic populations: alliance for clinical trials in oncology [Alliance]","volume":"140","author":"Mencia Trinchant","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.smim.2026.102029_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.smim.2026.102029_bib27","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/bloodadvances.2022007197","article-title":"Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia","volume":"6","author":"Muffly","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.smim.2026.102029_bib28","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1038\/s41467-021-26188-w","article-title":"The genomic landscape of Mexican Indigenous populations brings insights into the peopling of the Americas","volume":"12","author":"Garcia-Ortiz","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2026.102029_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.smim.2026.102029_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/01421598509036830","article-title":"CCTV in physiotherapy education--a survey of U.K. physiotherapy schools","volume":"7","author":"Brockie","year":"1985","journal-title":"Med Teach."},{"key":"10.1016\/j.smim.2026.102029_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/bloodadvances.2023011659","article-title":"Shrinking the divide: improving myeloma CART access","volume":"8","author":"Nooka","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.smim.2026.102029_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2026.102029_bib33","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2026.102029_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.smim.2026.102029_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.smim.2026.102029_bib36","article-title":"Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs","volume":"13","author":"Bustamante-Ogando","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40291-024-00719-9","article-title":"Talicabtagene autoleucel: first approval","volume":"28","author":"Nie","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.smim.2026.102029_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.19170","article-title":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"204","author":"Martinez-Cibrian","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.smim.2026.102029_bib40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Caldes","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ymthe.2024.12.034","article-title":"Choosing the right double-barreled gun: ARI0003 takes aim at lymphoma by targeting both CD19 and BCMA","volume":"33","author":"Rampotas","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2026.102029_bib42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12094-021-02757-9","article-title":"A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper","volume":"24","author":"Zozaya","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib43","article-title":"Decentralized point-of-care manufacturing of CD19 chimeric antigen receptor T cells in Mexico","volume":"11","author":"Salazar-Riojas","year":"2025","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"Kohl","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.smim.2026.102029_bib45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1470-2045(10)70127-3","article-title":"Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis","volume":"11","author":"Eapen","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/trf.14365","article-title":"Cord blood-derived T cells allow the generation of a more naive tumor-reactive cytotoxic T-cell phenotype","volume":"58","author":"Kwoczek","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.smim.2026.102029_bib48","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2026.102029_bib49","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.smim.2026.102029_bib50","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.smim.2026.102029_bib51","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2026.102029_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7903471","article-title":"Not all antibodies are created equal: factors that influence antibody mediated rejection","volume":"2017","author":"Butler","year":"2017","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.smim.2026.102029_bib53","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.smim.2026.102029_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.841117","article-title":"Cytokine release syndrome and associated acute toxicities in pediatric patients undergoing immune effector cell therapy or hematopoietic cell transplantation","volume":"12","author":"Baumeister","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.smim.2026.102029_bib55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.smim.2026.102029_bib56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41392-025-02512-4","article-title":"Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.smim.2026.102029_bib57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.smim.2026.102029_bib58","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.smim.2026.102029_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.smim.2026.102029_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing <em>in&\u266fxa0;vivo<\/em> CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.smim.2026.102029_bib61","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","article-title":"Circular RNAs: Characterization, cellular roles, and applications","volume":"185","author":"Liu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.smim.2026.102029_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"Tailor made: the art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2026.102029_bib63","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2025-4117","article-title":"Vivo pan CAR therapy utilizing circular RNA for treatment of multiple myeloma","volume":"146","author":"Silver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.smim.2026.102029_bib64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J. Immunother. Cancer"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532326000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532326000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:26Z","timestamp":1792788026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532326000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":64,"alternative-id":["S1044532326000163"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2026.102029","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to CAR-T therapy in Latin America: Barriers, gaps, and pathways forward","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2026.102029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102029"}}